TFE3 protein (Transcription Factor Binding to IGHM Enhancer 3) is a basic helix-loop-helix leucine zipper (bHLH-LZ) transcription factor encoded by the TFE3 gene. As a member of the MiT/TFE family alongside TFEB and MITF, TFE3 functions as a master regulator of lysosomal biogenesis, autophagy, and cellular stress responses by binding Coordinated Lysosomal Expression and Regulation (CLEAR) elements in target gene promoters. Its nuclear-cytoplasmic shuttling is controlled by mTORC1-dependent phosphorylation, and disruption of this regulation contributes to lysosomal dysfunction in Alzheimer's disease, Parkinson's disease, and Huntington's disease.
[^1]
[^2]
[^3]
[^4]
[^5]
[^6]
| Protein Name | Transcription factor E3 |
| Gene | [TFE3](/genes/tfe3) |
| UniProt ID | [P19532](https://www.uniprot.org/uniprot/P19532) |
| PDB IDs | [2H9D](https://www.rcsb.org/structure/2H9D) |
| Molecular Weight | 59.5 kDa |
| Subcellular Localization | Cytoplasm (inactive), Nucleus (active) |
| Protein Family | MiT/TFE family (bHLH-LZ) |
| Associated Diseases | [AD](/diseases/alzheimers-disease), [PD](/diseases/parkinsons-disease), [HD](/diseases/huntingtons-disease), Xp11 translocation RCC |
¶ Domain Architecture
TFE3 is a 575-amino acid protein with the following functional domains:
- Activation domain (N-terminal, residues 1-120): Transactivation region that recruits coactivators including CBP/p300
- Glutamine-rich region (residues 121-200): Additional transactivation surface
- Basic region (residues 261-280): DNA-binding domain that recognizes E-box (CANNTG) and CLEAR (GTCACGTGAC) motifs
- Helix-loop-helix domain (residues 281-330): Dimerization interface for homo- and heterodimerization with TFEB, MITF, and TFEC
- Leucine zipper (residues 331-370): Extended coiled-coil for stable dimer formation
- Regulatory region (C-terminal, residues 371-575): Contains mTORC1 phosphorylation sites (Ser321) and 14-3-3 binding motifs
The key regulatory mechanism governing TFE3 localization:
- Active mTORC1 phosphorylates TFE3 at Ser321 (and additional sites Ser246, Ser247)
- Phospho-Ser321 creates a high-affinity 14-3-3 binding site
- 14-3-3 binding masks the nuclear localization signal (NLS), retaining TFE3 in the cytoplasm
- Lysosomal stress / starvation: Calcineurin (activated by lysosomal Ca2+ release via MCOLN1/TRPML1) dephosphorylates Ser321
- Dephosphorylated TFE3 translocates to the nucleus and activates CLEAR element-containing genes
TFE3 forms functional dimers through its bHLH-LZ domain:
- TFE3-TFE3 homodimers: Most common form; strong CLEAR element affinity
- TFE3-TFEB heterodimers: Function cooperatively on shared target genes
- TFE3-MITF heterodimers: Primarily in melanocytes and microglial cells
- Dimerization is required for DNA binding and transcriptional activity
TFE3 drives expression of the entire lysosomal gene network:
- Over 400 direct transcriptional targets with CLEAR elements
- Coordinates lysosomal enzyme production, membrane protein insertion, and acidification
- Upregulates lysosomal exocytosis machinery for cellular clearance
- Activates lipophagy genes for lipid droplet catabolism
TFE3 induces genes at every step of the autophagy cascade:
- Initiation: ULK1, ULK2, FIP200, ATG13
- Nucleation: BECN1, VPS34, ATG14
- Elongation: ATG5, ATG7, ATG12, LC3/GABARAP
- Cargo recognition: SQSTM1/p62, NBR1, OPTN, TAX1BP1
- Fusion and degradation: STX17, VAMP8, lysosomal hydrolases
TFE3 integrates lysosomal status with metabolic programs:
- Starvation activates TFE3, promoting autophagy for nutrient recycling
- TFE3 induces oxidative metabolism genes including PGC-1α targets
- In the brain, TFE3 helps neurons adapt to metabolic stress by enhancing lysosomal capacity
Lysosomal dysfunction is an early and central feature of AD:
- mTORC1 hyperactivation (driven by Aβ and tau) traps TFE3 in the cytoplasm
- TFE3 nuclear levels are reduced in hippocampal neurons of AD patients
- Constitutively active TFE3 (S321A) reduces amyloid plaque burden in APP/PS1 mice by ~40%
- TFE3 activation enhances lysosomal degradation of both Aβ and phospho-tau
- Combined TFE3/TFEB activation shows greater benefit than either alone
- α-Synuclein aggregates impair lysosomal acidification and trap TFE3 in the cytoplasm
- GBA1 mutations reduce glucocerebrosidase activity, activating TFE3 as compensation (insufficient in disease)
- LRRK2 G2019S increases mTORC1 activity, suppressing TFE3 nuclear translocation
- AAV-TFE3 gene therapy in dopaminergic neurons attenuates α-synuclein toxicity in rat PD models
- Mutant huntingtin physically sequesters TFE3 in cytoplasmic aggregates
- TFE3 activation through trehalose or mTORC1 inhibition reduces polyQ aggregation
- Combined TFEB/TFE3 double activation clears mutant huntingtin more effectively than single activation
TFE3 is constitutively activated in Pompe disease, Gaucher disease, Niemann-Pick C, and other LSDs — reflecting compensatory lysosomal biogenesis. Additional TFE3 activation via gene therapy can augment this response.
- mTORC1 inhibitors: Rapamycin, Torin1 promote TFE3 nuclear translocation
- Trehalose: mTOR-independent TFE3/TFEB activator with neuroprotective effects
- TRPML1/MCOLN1 agonists: ML-SA1, SF-51 activate calcineurin-dependent TFE3 dephosphorylation
- AAV-TFE3 gene therapy: Direct overexpression in target neurons; in preclinical testing
- TFE3-S321A variant: Constitutively nuclear, bypasses mTORC1 regulation